The Web's Daily Resource for PF News
Live Last read · last published · next check
A new type of pericyte called Peri2 is linked to scar tissue formation in the lungs of people with pulmonary fibrosis (PF), according to a study. Pericytes are cells that surround blood vessels. A gene called FOXF1 was also shown to help control whether these cells stay healthy or switch into a damaging, fibrosis-driving state. […] The post Study links new cell type to lung scarring in pulmonary…
In case you hadn’t noticed, I didn’t file a column last week. I missed you and feel like I need to explain. My body told me I needed to take a break. I had back-to-back medical appointments that left me wiped out, so I decided to listen to my body. Little did I know at […] The post Recent health setbacks require us to find a more accessible home appeared first on Pulmonary Fibrosis News .
According to its U.S. developer, the first of two global clinical trials designed to test Haduvio (nalbuphine extended-release) — a potential treatment for chronic cough due to idiopathic pulmonary fibrosis (IPF) — is now underway, with the second expected to launch later this year. The initial Phase 3 trial, dubbed OCEAN-1 (NCT07671911), is evaluating the […] The post First global trial now…
The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical trial, and a Phase 2 study to further test it is underway, the treatment’s developer said. The Phase 2 trial, INFLO-2 (NCT07679893), aims to enroll more than 200 adults with IPF, ages 40 to 80, who […] The post Inhaled IPF therapy moves to Phase 2 as early trial shows promise…
Idiopathic pulmonary fibrosis (IPF) is emerging as a “hot spot” for drug development research, according to the nonprofit CheckOrphan, which notes that “investor and industry interest is accelerating.” A May 2026 article on the organization’s website notes recent activity by Avalyn Pharma, which has secured $100 million in research funding, along with recent moves by […] The post Hopeful about the…
Up until my husband, Donnie, became ill with pulmonary fibrosis, our family had been relatively healthy and free of any major issues. Each of us made it to our annual checkups, plus an additional appointment or two during cold and flu season. We probably had a handful of prescriptions between the four of us, and […] The post Managing the medical costs associated with chronic illness appeared first…
An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now recruiting participants at sites in five countries. The Phase 2 trial, dubbed RENEW (NCT06968845), aims to enroll approximately 120 people with IPF, ages 40 and older. Eligible participants will have been diagnosed within the last five years […] The post…
Rehabilitation from serious health setbacks is hard. This week has repeatedly proven that to me. Since being diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I’ve learned a lot about the disease. But I haven’t learned everything yet. During my IPF journey, I wasn’t hospitalized after my diagnosis until I received a bilateral lung […] The post Post-hospitalization rehabilitation…
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing authorization from the European Commission follows a positive recommendation from a regulatory committee and marks the first new IPF therapy approved in the EU in more than a decade, […] The post EU approves…
When my husband and I decided to move to a small farm, we imagined early mornings feeding chickens, tending the garden together, and watching cattle graze in the distance. It wasn’t simply a place to live. It was the life we had dreamed of building. No one imagines that one day their own body will become the biggest obstacle to living […] The post Life on the farm looks different with pulmonary…
